Referencie

1. 07-07617 Tytgat GN Hyoscine butylbromide: a review of its use in the treatment of abdominal cramping and pain. Drugs 67 (9), 1343 – 1357 (2007).
2. 2- U103461-01 27 Jul 2010, Study Number:2002.839 Wang F., Feister Bell H., Thowal S. A double blind, placebo-controlled, randomized, parallel-group pilot study of the efficacy and safety of oral dosis of 20mg hyoscine butylbromide.
3. P13-08760 Lacy BE, Wang Fm Bowal S, Schaefer EOn-demand hyoscine butylbromide for the treatment of self-reported functional cramping abdominal pain. Scand J Gastroenterol 48 (8), 926 -935 (2013).
4. P11- 06251 Mueller-Lissner S, Schaefer E, Kondla ASymptoms and their interpretation in patients self-treating abdominal cramping and pain with a spasmolytic (butylscopolamine bromide) – a pharmacy-based survey. Pharmacol Pharm 2, 82 – 87 (2011).
5. Source: IMS OTC Analyzer Jun 2015
6. P12-12472 Krueger D, Michael K, Allam S, Zeller F, Demir IE, Ceyhan G, Weiser T, Schemann MEffect of hyoscine butylbromide (Buscopan) on cholinergic pathways in the human intestine. 20th United Eur Gastroenterology week (UEGW), Amsterdam,20-24 Oct 2012
7. Company Core Data Sheet No 0057-06 18 October 2010 Buscopan Compositum
8. Epidemiological Study – Multi-Country – 2004 IPSOS
9. Growth Potential Study – Multi-Country – ISM 2015
10. Passos MDCF Diagnosis and Treatment. GED gastroenterol. endosc. Dig 2012; 31(2): 71-74
11. Sampaio HAC. Nutritional aspects related to the menstrual cycle. Rev Nutr 2002; 15(3): 309-317
12. QUDAL – QUality meDAL HEALTH SLOVAKIA, výsledky prieskumu platné pre 2020/2021 a územie Slovenskej republiky. Prieskum uskutočnený v 04/2020 na vzorke 1200 respondentov vo veku 17+, ktorí casto navštevujú lekáreň.